Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyQualChoice abrocitinib (Cibinqo) Coverage & Prior …
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PCH.57

    Abrocitinib (Cibinqo) — Coverage Criteria for Atopic Dermatitis

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PCH.57 alerts

    Get alerted when Policy CP.PCH.57 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, dosing limits, and prior authorization requirements for abrocitinib (Cibinqo) for commercial and HIM lines of business for patients age ≥12 with moderate-to-severe atopic dermatitis.

    Policy Summary
    PayerQualChoice
    PolicyAbrocitinib (Cibinqo) — Coverage Criteria for Atopic Dermatitis
    Policy CodePolicy CP.PCH.57
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation demonstrating diagnosis, extent of disease, specialist involvement, treatment history, and dosing justification.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12min patient age
    BSA ≥10% / special areasdisease extent
    100 mg/dayroutine max dose
    200 mg/dayhigher dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    approval length
    3tablet strengths

    Coverage Criteria for Abrocitinib (Cibinqo)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval - Atopic Dermatitis: 1. Diagnosis of atopic dermatitis (AD) affecting one of the following: (a) at least 10% of the member's body surface area (BSA); OR (b) involvement of hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas.; 2. Prescribed by or in consultation with a dermatologist or allergist.; 3. Age ≥ 12 years.; 4. Failure of BOTH of the following, unless contraindicated or clinically significant adverse effects occur: (a) two formulary medium to very high potency topical corticosteroids, each used for ≥ 2 weeks; AND (b) one non‑steroidal topical therapy used for ≥ 4 weeks (e.g., topical calcineurin inhibitor such as tacrolimus 0.03% ointment or pimecrolimus 1% cream, or crisaborole/Eucrisa).; 5. Failure of Dupixent and Rinvoq, each used for > consecutive 4 months, unless clinically significant adverse effects occur or both are contraindicated (note: for Illinois HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395).; 6. Cibinqo (abrocitinib) is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Dupixent) or another JAK inhibitor (e.g., Olumiant, Rinvoq, Opzelura).; 7. Dose does not exceed one of the following: (a) 100 mg per day AND one tablet per day; OR (b) 200 mg per day AND one tablet per day when medical justification documents inadequate response to 100 mg daily after 12 weeks.see text

    Follow dosing limits and step therapy/IL statutory exception as noted in source.

    Continuation Therapy

    Continued therapy covered when ALL of the following are met:

    Continued Therapy - Atopic Dermatitis: 1. Member meets one of the following: (a) currently receiving medication via the Centene benefit or previously met initial approval criteria; OR (b) currently receiving medication and enrolled in a state/product with continuity of care regulations.; 2. Member is responding positively to therapy as evidenced by, but not limited to, reduction in itching and scratching.; 3. Cibinqo (abrocitinib) is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Dupixent) or another JAK inhibitor (e.g., Olumiant, Rinvoq, Opzelura).; 4. Dose does not exceed one of the following: (a) 100 mg per day AND one tablet per day; OR (b) 200 mg per day AND one tablet per day when medical justification supports inadequate response to 100 mg daily after 12 weeks.see text

    Approval duration for continuation is 12 months.

    Non‑FDA approved indications not addressed in this policy are excluded from coverage unless the provider supplies sufficient documentation of efficacy and safety per the Health Plan off‑label use policies (see CP.CPA.09 for commercial lines and HIM.PA.154 for marketplace) or as otherwise permitted by applicable evidence of coverage documents.

    Key Clinical Thresholds and Definitions

    Body Surface Area (BSA) — threshold
    BSA thresholdAt least 10% of the member's body surface area (BSA)
    Special-area involvementAlternatively, involvement of hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas
    Abbreviations
    ADAtopic dermatitis
    BSABody surface area
    FDAFood and Drug Administration

    Provider Requirements, Prior Auth, and Documentation

    Prior Authorization

    Prior authorization required — document diagnosis, extent, specialty, age, treatment and dosing

    Prior authorization is required. Provider must document the diagnosis, extent of disease (BSA ≥10% or involvement of specified special areas), prescribing clinician specialty (prescribed by or in consultation with a dermatologist or allergist), patient age (≥12 years), treatment history, and dosing limits to support initial approval.

    • Demonstrate diagnosis and extent of disease per policy (BSA ≥10% or involvement of hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas).
    • Confirm prescriber is a dermatologist or allergist or that the request is in consultation with one.
    • Provide age verification (patient ≥ 12 years), prior treatment history, and planned dose (≤100 mg/day or justification for 200 mg/day).
    Step Therapy

    Step therapy — topical and systemic agent failures required before approval

    Step therapy must be documented before approval: failure of topical corticosteroids and a non‑steroidal topical therapy is required, and failure of Dupixent and Rinvoq each for > consecutive 4 months is also required unless contraindicated or not tolerated.

    Background and Clinical Context

    Atopic dermatitis (AD) is typically managed with topical emollients and corticosteroids as first‑line therapy; topical calcineurin inhibitors are used for patients who cannot use topical steroids or require steroid‑sparing treatment. For moderate‑to‑severe or refractory disease, systemic therapies including biologic agents and oral Janus kinase (JAK) inhibitors such as abrocitinib (Cibinqo) are considered when inadequate control is achieved with optimized topical and non‑systemic regimens.

    This policy addresses use of abrocitinib for patients aged ≥ 12 years with moderate‑to‑severe atopic dermatitis who meet disease extent criteria (e.g., BSA ≥ 10% or involvement of special areas) and step‑therapy requirements, specifies dosing limits (routine 100 mg/day with escalation to 200 mg/day only after documented inadequate response to 100 mg for 12 weeks), and requires prior authorization with supporting clinical documentation.

    Policy Revision History

    2025-12-01policy_effectiveLatest

    Clinical policy CP.PCH.57 (Abrocitinib/Cibinqo) effective date published as 2025-12-01.

    Policy Summary
    PayerQualChoice
    PolicyAbrocitinib (Cibinqo) — Coverage Criteria for Atopic Dermatitis
    Policy CodePolicy CP.PCH.57
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation demonstrating diagnosis, extent of disease, specialist involvement, treatment history, and dosing justification.
    SourceLink
    On This Page
    Coverage Criteria for Abrocitinib (Cibinqo)Key Clinical Thresholds and DefinitionsProvider Requirements, Prior Auth, and DocumentationBackground and Clinical ContextPolicy Revision History
    Product availability — tablet strengths
    Tablet strengths50 mg
    Tablet strengths100 mg
    Tablet strengths200 mg
    • Failure of two formulary medium to very high potency topical corticosteroids, each used for ≥2 weeks.
    • Failure of one non‑steroidal topical therapy used for ≥4 weeks (e.g., topical calcineurin inhibitor or Eucrisa).
    • Failure of Dupixent and Rinvoq, each used for > consecutive 4 months, unless clinically significant adverse effects occur or both are contraindicated.
    • Illinois HIM requests: step therapy requirements do not apply as of 1/1/2026 per IL HB 5395 (where applicable).
    Documentation Required

    Required clinical documentation — submit office notes, labs, and prior-therapy records

    Submit supporting clinical documentation with the authorization request: office chart notes, lab results, or other clinical information demonstrating the member meets all approval criteria.

    • Office visit/chart notes documenting diagnosis, BSA or special-area involvement, symptoms and response to prior therapies.
    • Records of prior topical therapy use (agents, potency, duration) and systemic biologic/JAK inhibitor therapy with dates and reasons for discontinuation.
    • Documentation of prescriber specialty or consultation with a dermatologist/allergist, and dosing rationale if requesting >100 mg/day.
    Denial Risk

    Documentation-based denials — missing required records or insufficient off‑label evidence may lead to denial

    Requests missing required documentation that the member meets all approval criteria, or requests for non‑FDA indications without sufficient off‑label evidence, may be denied.

    • Lack of documentation showing required topical/systemic treatment failures, prescriber specialty, age, extent of disease, or dosing justification may result in denial.
    • Non‑FDA uses not addressed by this policy require sufficient documentation of efficacy and safety per off‑label use policies; otherwise coverage is not authorized.
    Note

    Prior authorization guidance — policy as a guide to coverage decisions and benefits administration

    This clinical policy is a guide to medical necessity to assist coverage decisions and administering benefits; prior authorization requirements are determined per the Health Plan and membership documents.

    • Use this policy to inform coverage decisions and benefit administration, but follow Health Plan-specific prior authorization procedures and membership terms.
    • The policy does not guarantee payment and may be changed by the Health Plan as needed.
    Billing Rule

    Preferred-agent redirection — Dupixent and Rinvoq included in step requirements

    Initial approval criteria were adapted to redirect to preferred agents Dupixent and Rinvoq; failure of these preferred agents (used > consecutive 4 months each) is required unless contraindicated or adverse effects occur.

    • Policy creation note added redirection to preferred agents Dupixent and Rinvoq for atopic dermatitis initial approval.
    • Failure of Dupixent and Rinvoq, each used for > consecutive 4 months, is required unless clinically significant adverse effects occur or both are contraindicated.
    Note

    Provider professional judgment — apply clinical judgment; coverage still subject to plan terms

    Coverage determinations guided by this clinical policy remain subject to the terms of the member's coverage documents; providers are expected to exercise professional medical judgment when treating patients.

    • Providers should apply their clinical judgment; this policy is not intended to dictate medical practice.
    • Coverage and administration of benefits remain subject to all plan terms, conditions, exclusions, limitations, and applicable law.
    Note

    Coverage terms and limitations — determinations subject to plan documents, exclusions, and legal requirements

    All coverage decisions and benefit administration are subject to the member's evidence of coverage, certificate of coverage, policy, contract, exclusions, limitations, and applicable state/federal requirements and Health Plan administrative policies.

    • Decisions must conform to the specific plan's terms, conditions, exclusions, and limitations.
    • Non‑FDA indications not addressed in this policy are excluded unless sufficient off‑label documentation is provided per off‑label use policies.